» Articles » PMID: 11744725

Vimentin Exposed on Activated Platelets and Platelet Microparticles Localizes Vitronectin and Plasminogen Activator Inhibitor Complexes on Their Surface

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2001 Dec 18
PMID 11744725
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Type 1 plasminogen activator inhibitor (PAI-1), the primary inhibitor of tissue-type plasminogen activator (t-PA), is found in plasma and platelets. PAI-1 circulates in complex with vitronectin (Vn), an interaction that stabilizes PAI-1 in its active conform. In this study, we examined the binding of platelet-derived Vn and PAI-1 to the surface of isolated platelets. Flow cytometry indicate that, like P-selectin, PAI-1, and Vn are found on the surface of thrombin- or calcium ionophore-activated platelets and platelet microparticles. The binding of PAI-1 to the activated platelet surface is Vn-dependent. Vn mediates the binding of PAI-1 to platelet surfaces through a high affinity (K(d) of 80 nm) binding interaction with the NH(2) terminus of vimentin, and this Vn-binding domain is expressed on the surface of activated platelets and platelet microparticles. Immunological and functional assays indicate that only -5% of the total PAI-1 in platelet releasates is functionally active, and it co-precipitates with Vn, and the vimentin-enriched cytoskeleton fraction of activated platelet debris. The remaining platelet PAI-1 is inactive, and does not associate with the cytoskeletal debris of activated platelets. Confocal microscopic analysis of platelet-rich plasma clots confirm the co-localization of PAI-1 with Vn and vimentin on the surface of activated platelets, and platelet microparticles. These findings suggest that platelet vimentin may regulate fibrinolysis in plasma and thrombi by binding platelet-derived Vn.PAI-1 complexes.

Citing Articles

The Cancer Chimera: Impact of Vimentin and Cytokeratin Co-Expression in Hybrid Epithelial/Mesenchymal Cancer Cells on Tumor Plasticity and Metastasis.

Kuburich N, Kiselka J, den Hollander P, Karam A, Mani S Cancers (Basel). 2025; 16(24.

PMID: 39766058 PMC: 11674825. DOI: 10.3390/cancers16244158.


Extracellular vimentin amplifies inflammation: Perspectives for immune injury and therapeutics for periodontitis.

Yuan Z, Smith P, McCulloch C FASEB J. 2025; 39(1):e70286.

PMID: 39758044 PMC: 11701797. DOI: 10.1096/fj.202402322R.


Serotonin Signaling and the Hyperpermeable Endothelial Barrier in Sepsis: Clues to a Molecular Mechanism.

Kilic F J Community Med Public Health. 2024; 7(4).

PMID: 38371611 PMC: 10871023. DOI: 10.29011/2577-2228.100389.


Vimentin takes a hike - Emerging roles of extracellular vimentin in cancer and wound healing.

Parvanian S, Coelho-Rato L, Patteson A, Eriksson J Curr Opin Cell Biol. 2023; 85:102246.

PMID: 37783033 PMC: 11214764. DOI: 10.1016/j.ceb.2023.102246.


Vimentin is an important ACE2 co-receptor for SARS-CoV-2 in epithelial cells.

Arrindell J, Abou Atmeh P, Jayet L, Sereme Y, Mege J, Desnues B iScience. 2022; 25(11):105463.

PMID: 36338433 PMC: 9618295. DOI: 10.1016/j.isci.2022.105463.